The Developmental Research Program (DRP) of the Pacific Northwest (PNW) Prostate Cancer SPORE is designed to solicit, evaluate, and support innovative pilot projects in translational prostate cancer research. Projects funded under the DRP are intended to rapidly advance a new idea or concept that has the potential to substantially impact our understanding of prostate cancer, and ultimately influence the clinical management of this disease through improved prevention and treatment strategies. Since the inception of the PNW Prostate Cancer SPORE, the infrastructure of the DRP has established mechanisms to quickly respond to translational research opportunities within the PNW SPORE institutions that require support to advance hypotheses or confirm feasibility in order to justify larger resource investments. Developmental projects include research in basic science, clinical science, and population-based studies, and will continue to build collaborations between PNW SPORE sites and other institutions with SPOREs in prostate cancer. Developmental projects will be selected based on their potential to mature into translational research studies that will receive independent funding, either within our SPORE, or from philanthropic, foundation or government sources. The DRP is designed to attract both senior investigators with diverse scientific expertise and investigators new to translational prostate cancer research.

Public Health Relevance

Investments in early-stage innovative ideas are essential for ensuring that new concepts and approaches can be rapidly directed toward improving our understanding, prevention, and treatment of prostate cancer. Through the Developmental Research Program, the PNW SPORE environment will provide multidisciplinary resources to advance novel scientific ideas, continue an organized, rigorous, and consistent program to fund and promote early-stage projects, and cultivate the recruitment of new and established investigators in prostate cancer translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-12
Application #
8933582
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2002-09-19
Project End
2018-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
12
Fiscal Year
2014
Total Cost
$165,573
Indirect Cost
$63,739
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Mateo, Joaquin; Cheng, Heather H; Beltran, Himisha et al. (2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 73:687-693
Lim, Daniel M; Gulati, Roman; Aleshin-Guendel, Serge et al. (2018) Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237
Lee, Chung C W; Munuganti, Ravi Shashi Nayana; Peacock, James W et al. (2018) Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc 2:1381-1394
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53

Showing the most recent 10 out of 400 publications